BWX Technologies, Inc. manufactures and sells nuclear components in the United States, Canada, and internationally. The company is headquartered in Lynchburg, Virginia.
| Revenue (TTM) | $3.51B |
| Gross Profit (TTM) | $775.94M |
| EBITDA | $476.49M |
| Operating Margin | 10.40% |
| Return on Equity | 28.30% |
| Return on Assets | 5.53% |
| Revenue/Share (TTM) | $38.35 |
| Book Value | $14.56 |
| Price-to-Book | 11.89 |
| Price-to-Sales (TTM) | 4.47 |
| EV/Revenue | 4.918 |
| EV/EBITDA | 29.68 |
| Quarterly Earnings Growth (YoY) | 14.10% |
| Quarterly Revenue Growth (YoY) | 18.00% |
| Shares Outstanding | $91.62M |
| Float | $91.24M |
| % Insiders | 0.35% |
| % Institutions | 94.35% |
Volatility is currently contracting
The collaboration advances ANEEL's technical and regulatory qualification ahead of commercial reactor demonstration. Pictured: In the front row from left to right, John D'Angelo (President of Kinectrics) and Milan Shah (COO of CCTE).
BWX Technologies expands its nuclear services portfolio through decommissioning, remediation, waste management and nuclear site support.
BWXT expands its commercial nuclear portfolio through nuclear medicine, isotope production and radiopharmaceutical capabilities.
BWX Technologies (BWXT) earns a hold rating due to strong fundamentals but limited upside at current valuation. Naval business provides multi-year revenue visibility, supported by a $6.93 billion Government Operations backlog. Commercial Operations offers growth potential, with 39% organic revenue growth in Q1 2026 and margin expansion opportunities.
The Department of Energy (DOE) has narrowed the competition for its proposed Nuclear Lifecycle Innovation Campuses (NLICs) to five states: Utah, Tennessee, Oklahoma, Louisiana, and Idaho. The selection advances an effort that could create new investment and contracting opportunities across nearly every part of the nuclear value chain.
Artificial intelligence has an electricity problem, and nuclear is the answer investors keep circling back to.
BWXT raises its 2026 outlook as stronger operations support higher guidance, while a medical divestiture and PCG deal sharpen its nuclear focus.
BWX Technologies, Inc. (BWXT) Q2 2026 Earnings Call Transcript
LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) announced today it has entered into a definitive agreement to sell its medical business to Nordic Capital, an experienced healthcare investor with broad expertise and a deep understanding of the radiopharmaceutical industry and its value chain. The transaction, valued at up to $800 million, includes BWXT Medical and Kinectrics' stable medical isotopes business. The sale will enable BWXT to concentrate resources and capital on.
BWXT heads into Q2 with nuclear, medical and defense demand supporting sales, while earnings are expected to edge lower.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BWXT and any ticker you trade — then tracks every position and per-strategy win rate.
